Global Hemophilia Therapeutics Market 2020-2024 | Evolving Opportunities with Bayer AG and CSL Ltd. | Technavio

The global hemophilia therapeutics market is poised to grow by USD 4.19 billion during 2020-2024, progressing at a CAGR of over 6% during the forecast period. Request free sample pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226005418/en/

Technavio has announced its latest market research report titled Global Hemophilia Therapeutics Market 2020-2024 (Graphic: Business Wire)

Read the 120-page report with TOC on "Hemophilia Therapeutics Market Analysis Report by Type (Hemophilia A, Hemophilia B, and Hemophilia C), Geographic Segmentation (North America, Europe, Asia, and ROW), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/hemophilia-therapeutics-market-industry-analysis

The market is driven by the increasing number of initiatives to create awareness about hemophilia. In addition, R&D of novel strategies to develop therapeutics is anticipated to boost the growth of the hemophilia therapeutics market.

The lack of awareness of hemophilia has proved to be one of the biggest barriers in the adoption of therapeutics for hemophilia. As a result, public and private organizations are introducing initiatives around the globe to boost the awareness about different types of hemophilia. For instance, organizations such as the National Hemophilia Foundation and the World Federation of Hemophilia support seek to create awareness about the condition. The awareness initiatives include educating patients on advances and discoveries of medicines for the treatment of disease. The campaigns also involve disseminating information on bleeding disorders, training healthcare professionals, and organizing regional workshops. Thus, the increasing number of initiatives to create awareness about hemophilia is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Hemophilia Therapeutics Market Companies:

Bayer AG

Bayer AG is headquartered in Ireland and operates the business under various segments such as Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. The company offers JIVI and KOVALTRY.

CSL Ltd.

CSL Ltd. offers products through the following business units: CSL Behring and Seqirus. The company offers hemophilia therapeutics under the brand, AFSTYLA. Beriate, Biostate, Cluviat, Corifact, Factor X P Behring, Fibrogammin, Haemate, Haemocomplettan, Humate-P, IDELVION, and Voncento are among the product offerings.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. operates under various business segments, namely Pharmaceuticals and Diagnostics. The company offers HEMLIBRA, which is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients.

Grifols SA

Grifols SA offers products through the following business segments: Bioscience, Diagnostic, Hospital, and Bio supplies. The company offers ALPHANATE, PROFILNINE, and AlphaNine SD.

Novo Nordisk AS

Novo Nordisk AS offers products through the following business segments: Diabetes and obesity, and Biopharmaceuticals. The company offers NovoSeven, recombinant factor VIIa, NovoEight, recombinant factor VIII, NovoThirteen, recombinant factor XIII, and Refixia, Nonacog beta pegol; N9/GP.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Hemophilia Therapeutics Market Type Outlook (Revenue, USD Billion, 2020-2024)

• Hemophilia A
• Hemophilia B
• Hemophilia C

Hemophilia Therapeutics Market Geographic Outlook (Revenue, USD Billion, 2020-2024)

• North America
• Europe
• Asia
• ROW

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care Include:

Artificial Blood Substitutes Market – Global Artificial Blood Substitutes Market by product (HBOC and PFBOC) and geography (Asia, Europe, North America, and ROW).

Blood Grouping Reagents Market – Global Blood Grouping Reagents Market by geography (Asia, Europe, North America, and ROW) and end-user (hospitals and blood banks; clinical laboratories; and academic and research institutes).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005418/en/